Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis
Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole‐body tum...
Saved in:
Published in | American journal of medical genetics. Part A Vol. 164A; no. 6; pp. 1431 - 1437 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Blackwell Publishing Ltd
01.06.2014
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
ISSN | 1552-4825 1552-4833 1552-4833 |
DOI | 10.1002/ajmg.a.36466 |
Cover
Abstract | Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole‐body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF‐36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole‐body MRI. One‐sample t‐tests were used to compare norm‐based SF‐36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease‐specific clinical variable were used to relate whole‐body tumor volume to QOL scales. Two hundred forty‐five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF‐36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF‐36 bodily pain subscale (rho = −0.287, P = 0.04) and VAS (rho = 0.34, P = 0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF‐36 (P = 0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor‐focused therapies such as surgery by including psychosocial interventions. © 2014 Wiley Periodicals, Inc. |
---|---|
AbstractList | Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole-body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF-36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole-body MRI. One-sample t-tests were used to compare norm-based SF-36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease-specific clinical variable were used to relate whole-body tumor volume to QOL scales. Two hundred forty-five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF-36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF-36 bodily pain subscale (rho = -0.287, P = 0.04) and VAS (rho = 0.34, P = 0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF-36 (P = 0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor-focused therapies such as surgery by including psychosocial interventions.Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole-body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF-36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole-body MRI. One-sample t-tests were used to compare norm-based SF-36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease-specific clinical variable were used to relate whole-body tumor volume to QOL scales. Two hundred forty-five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF-36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF-36 bodily pain subscale (rho = -0.287, P = 0.04) and VAS (rho = 0.34, P = 0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF-36 (P = 0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor-focused therapies such as surgery by including psychosocial interventions. Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole‐body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF‐36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole‐body MRI. One‐sample t‐tests were used to compare norm‐based SF‐36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease‐specific clinical variable were used to relate whole‐body tumor volume to QOL scales. Two hundred forty‐five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF‐36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF‐36 bodily pain subscale (rho = −0.287, P = 0.04) and VAS (rho = 0.34, P = 0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF‐36 (P = 0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor‐focused therapies such as surgery by including psychosocial interventions. © 2014 Wiley Periodicals, Inc. Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole-body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF-36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole-body MRI. One-sample t-tests were used to compare norm-based SF-36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease-specific clinical variable were used to relate whole-body tumor volume to QOL scales. Two hundred forty-five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF-36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF-36 bodily pain subscale (rho = -0.287, P = 0.04) and VAS (rho = 0.34, P = 0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF-36 (P = 0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor-focused therapies such as surgery by including psychosocial interventions. Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole-body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF-36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole-body MRI. One-sample t-tests were used to compare norm-based SF-36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease-specific clinical variable were used to relate whole-body tumor volume to QOL scales. Two hundred forty-five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF-36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF-36 bodily pain subscale (rho=-0.287, P=0.04) and VAS (rho=0.34, P=0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF-36 (P=0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor-focused therapies such as surgery by including psychosocial interventions. © 2014 Wiley Periodicals, Inc. [PUBLICATION ABSTRACT] Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have demonstrated that patients with NF1 and NF2 have reduced quality of life (QOL), but no studies have examined the relationship between whole-body tumor burden and QOL in these patients. We administered a QOL questionnaire (the SF-36) and a visual analog pain scale (VAS) to a previously described cohort of adult neurofibromatosis patients undergoing whole-body MRI. One-sample t-tests were used to compare norm-based SF-36 scores to weighted population means. Spearman correlation coefficients and multiple linear regression analyses controlling for demographic and disease-specific clinical variable were used to relate whole-body tumor volume to QOL scales. Two hundred forty-five patients (142 NF1, 53 NF2, 50 schwannomatosis) completed the study. Subjects showed deficits in selected subscales of the SF-36 compared to adjusted general population means. In bivariate analysis, increased tumor volume was significantly associated with pain in schwannomatosis patients, as measured by the SF-36 bodily pain subscale (rho=-0.287, P=0.04) and VAS (rho=0.34, P=0.02). Regression models for NF2 patients showed a positive relationship between tumor burden and increased pain, as measured by the SF-36 (P=0.008). Patients with NF1, NF2, and schwannomatosis suffer from reduced QOL, although only pain shows a clear relationship to patient's overall tumor burden. These findings suggest that internal tumor volume is not a primary contributor to QOL and emphasize the need for comprehensive treatment approaches that go beyond tumor-focused therapies such as surgery by including psychosocial interventions. copyright 2014 Wiley Periodicals, Inc. |
Author | Plotkin, Scott R. Merker, Vanessa L. Nguyen, Rosa Cai, Wenli Harris, Gordon J. Bredella, Miriam A. Mautner, Victor F. Kassarjian, Ara Muzikansky, Alona |
Author_xml | – sequence: 1 givenname: Vanessa L. surname: Merker fullname: Merker, Vanessa L. organization: Department of Neurology and Cancer Center, Massachusetts General Hospital, Massachusetts, Boston – sequence: 2 givenname: Miriam A. surname: Bredella fullname: Bredella, Miriam A. organization: Department of Radiology, Massachusetts General Hospital, Massachusetts, Boston – sequence: 3 givenname: Wenli surname: Cai fullname: Cai, Wenli organization: Department of Radiology, Massachusetts General Hospital, Massachusetts, Boston – sequence: 4 givenname: Ara surname: Kassarjian fullname: Kassarjian, Ara organization: Department of Radiology, Corades, S.L., Majadahonda, Spain – sequence: 5 givenname: Gordon J. surname: Harris fullname: Harris, Gordon J. organization: Department of Radiology, Massachusetts General Hospital, Massachusetts, Boston – sequence: 6 givenname: Alona surname: Muzikansky fullname: Muzikansky, Alona organization: Biostatistics Center, Massachusetts General Hospital, Massachusetts, Boston – sequence: 7 givenname: Rosa surname: Nguyen fullname: Nguyen, Rosa organization: Department of Pediatrics, University of Maryland, Baltimore, Maryland – sequence: 8 givenname: Victor F. surname: Mautner fullname: Mautner, Victor F. organization: Department of Neurology, University Hospital, Hamburg, Germany – sequence: 9 givenname: Scott R. surname: Plotkin fullname: Plotkin, Scott R. email: Correspondence to:Scott R. Plotkin, M.D., Ph.D., Yawkey 9E, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114., splotkin@partners.org organization: Department of Neurology and Cancer Center, Massachusetts General Hospital, Massachusetts, Boston |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/24664633$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc1v0zAYhyM0xLbCjTOyxIVDUxx_JTlWFRTQ-NAE4mg5zhvq4tiZ7ajrf0-6rjtMAnHyK-t5ftL7_i6zM-cdZNnLAi8KjMlbte1_LdSCCibEk-yi4JzkrKL07GEm_Dy7jHGLMcW8FM-yczKxTFB6kd1eg1XJeBc3ZkANpB2AQ7uNt5A3vt2jNPY-oGYMLbg50tY4o5VFwwacT_sB5ki5Ft2Mypq0R75D1nSAjEPDFAsuRbQzaYMcjMF3pgm-V8lHE59nTztlI7y4f2fZj_fvvq8-5Fdf1x9Xy6tcs5KKXFEhikqLsiEcTz8t60pcs6JSNdW8rjUVQAouVFkRjXkjSKVVyVrWAK1boekse3PMHYK_GSEm2ZuowVrlwI9RFpzUNadFXf8PShlmdLruLHv9CN36MbhpkQNVlJRNiRP16p4amx5aOQTTq7CXp_NPADkCOvgYA3RSm3RXRwrKWFlgeehYHjqWSt51PEnzR9Ip9y84O-I7Y2H_T1YuP31eL09aftRMTHD7oKnwW4qSllz-_LKW365ZvWJrIiv6B8WRx_Y |
CitedBy_id | crossref_primary_10_1002_jmri_25236 crossref_primary_10_1002_ajmg_a_37987 crossref_primary_10_1186_s13550_024_01189_0 crossref_primary_10_1002_acn3_51386 crossref_primary_10_1097_SAP_0000000000000494 crossref_primary_10_1227_neu_0000000000002242 crossref_primary_10_1007_s10897_016_9939_8 crossref_primary_10_1093_noajnl_vdaa003 crossref_primary_10_1093_nop_npae084 crossref_primary_10_1177_17407745231209224 crossref_primary_10_2147_PHMT_S362679 crossref_primary_10_1097_SCS_0000000000004685 crossref_primary_10_1016_j_det_2019_05_015 crossref_primary_10_1212_WNL_0000000000002929 crossref_primary_10_1212_WNL_0000000000002927 crossref_primary_10_1093_neuonc_nou235 crossref_primary_10_1007_s11060_016_2314_7 crossref_primary_10_1093_neuonc_nov200 crossref_primary_10_1007_s00381_020_04754_9 crossref_primary_10_1038_nrdp_2017_4 crossref_primary_10_1007_s00256_024_04765_6 crossref_primary_10_1016_j_jacr_2015_06_003 crossref_primary_10_1212_WNL_0000000000201535 crossref_primary_10_1038_s41598_019_49705_w crossref_primary_10_3389_fpubh_2024_1398803 crossref_primary_10_5209_PSIC_59173 crossref_primary_10_1016_j_ejim_2014_04_004 crossref_primary_10_1097_SCS_0000000000006015 crossref_primary_10_1016_j_spen_2024_101172 crossref_primary_10_1007_s10880_018_9584_5 crossref_primary_10_1093_noajnl_vdz045 crossref_primary_10_3171_CASE21176 crossref_primary_10_1186_s12883_019_1338_y crossref_primary_10_1093_noajnl_vdaa095 crossref_primary_10_1097_MAO_0000000000001019 crossref_primary_10_1111_jdv_18140 crossref_primary_10_1148_radiol_2016160293 crossref_primary_10_1007_s13235_024_00609_z crossref_primary_10_1177_0883073816666736 crossref_primary_10_1007_s00256_019_03290_1 crossref_primary_10_1007_s11916_024_01283_x crossref_primary_10_2147_JPR_S287603 crossref_primary_10_1080_13651501_2021_1921217 crossref_primary_10_1097_MD_0000000000009717 crossref_primary_10_14730_aaps_2020_02187 |
Cites_doi | 10.1002/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8 10.1002/1098-2779(2000)6:2<117::AID-MRDD5>3.0.CO;2-X 10.1111/j.1749-4486.2010.02176.x 10.1159/000337548 10.1080/87565641.2012.695831 10.1177/1087054712450749 10.1371/journal.pone.0035711 10.1148/radiol.2503080700 10.1001/archderm.137.11.1421 10.1212/01.WNL.0000163982.78900.AD 10.1212/01.wnl.0000179303.72345.ce 10.1212/01.WNL.0000035638.74084.F4 10.1097/00129492-200501000-00016 10.1002/ajmg.a.31422 10.1159/000187594 10.1634/theoncologist.2012-0162 10.7326/0003-4819-113-1-39 |
ContentType | Journal Article |
Copyright | 2014 Wiley Periodicals, Inc. |
Copyright_xml | – notice: 2014 Wiley Periodicals, Inc. |
DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7TK 8FD FR3 K9. P64 RC3 7X8 |
DOI | 10.1002/ajmg.a.36466 |
DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Technology Research Database Engineering Research Database ProQuest Health & Medical Complete (Alumni) Biotechnology and BioEngineering Abstracts Genetics Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Genetics Abstracts Technology Research Database ProQuest Health & Medical Complete (Alumni) Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE Genetics Abstracts Genetics Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
EISSN | 1552-4833 |
EndPage | 1437 |
ExternalDocumentID | 3296098901 24664633 10_1002_ajmg_a_36466 AJMGA36466 ark_67375_WNG_PR49C4G2_8 |
Genre | article Research Support, U.S. Gov't, Non-P.H.S Journal Article |
GrantInformation_xml | – fundername: Department of Defense Neurofibromatosis Research Program funderid: NF050202 |
GroupedDBID | --- .55 .GA .Y3 05W 0R~ 10A 1L6 1OB 1OC 23M 31~ 33P 3O- 4.4 50Y 51W 51X 52M 52N 52O 52P 52S 52T 52W 52X 53G 5GY 5VS 66C 6P2 702 7PT 8-1 8-4 8-5 8UM 930 A03 AAEVG AAHQN AAMMB AAMNL AANHP AANLZ AAONW AASGY AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ACAHQ ACBWZ ACCZN ACFBH ACGFO ACGFS ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADXAS ADZMN AEFGJ AEIGN AEIMD AENEX AEUYR AEYWJ AFBPY AFFPM AFGKR AFWVQ AFZJQ AGHNM AGQPQ AGXDD AGYGG AHBTC AIDQK AIDYY AITYG AIURR ALMA_UNASSIGNED_HOLDINGS ALUQN ALVPJ AMBMR AMYDB ATUGU AZBYB AZFZN BDRZF BFHJK BRXPI BSCLL BY8 C45 CO8 CS3 D-F DCZOG DPXWK DR2 DRFUL DRSTM EBD EBS EJD EMOBN F00 F01 F04 F5P FEDTE G-S GNP GODZA HBH HF~ HGLYW HHY HHZ HVGLF IX1 JPC KD1 KQQ L7B LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MK4 MRFUL MRSTM MSFUL MSSTM MXFUL MXSTM OIG OVD P2W P4D QB0 QRW ROL RX1 RYL SUPJJ SV3 TEORI UB1 V2E WIH WIK WJL WQJ X7M XG1 XV2 AAHHS AAYXX ACCFJ ADZOD AEEZP AEQDE AIWBW AJBDE CITATION CGR CUY CVF ECM EIF NPM 7QP 7TK 8FD FR3 K9. P64 RC3 7X8 |
ID | FETCH-LOGICAL-c4736-a36618c67b250473d4f709418a93c599c36e2156a782c05b628ca74d4be39d6c3 |
IEDL.DBID | DR2 |
ISSN | 1552-4825 1552-4833 |
IngestDate | Fri Sep 05 08:14:43 EDT 2025 Fri Sep 05 06:43:26 EDT 2025 Wed Aug 13 06:43:43 EDT 2025 Thu Apr 03 07:09:16 EDT 2025 Thu Apr 24 23:02:45 EDT 2025 Tue Jul 01 00:44:58 EDT 2025 Sun Sep 21 06:21:48 EDT 2025 Sun Sep 21 06:20:55 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | pain nerve sheath tumor whole-body MRI schwannomatosis neurofibromatosis 2 quality of life neurofibromatosis 1 SF-36 |
Language | English |
License | http://onlinelibrary.wiley.com/termsAndConditions#vor 2014 Wiley Periodicals, Inc. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4736-a36618c67b250473d4f709418a93c599c36e2156a782c05b628ca74d4be39d6c3 |
Notes | ark:/67375/WNG-PR49C4G2-8 Department of Defense Neurofibromatosis Research Program - No. NF050202 istex:AD4AC3C5D68AF2868E3D3D9BD3E979D404034985 ArticleID:AJMGA36466 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 14 ObjectType-Article-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://nrs.harvard.edu/urn-3:HUL.InstRepos:33788496 |
PMID | 24664633 |
PQID | 1521734319 |
PQPubID | 2028748 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_1529953199 proquest_miscellaneous_1523404348 proquest_journals_1521734319 pubmed_primary_24664633 crossref_citationtrail_10_1002_ajmg_a_36466 crossref_primary_10_1002_ajmg_a_36466 wiley_primary_10_1002_ajmg_a_36466_AJMGA36466 istex_primary_ark_67375_WNG_PR49C4G2_8 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | June 2014 |
PublicationDateYYYYMMDD | 2014-06-01 |
PublicationDate_xml | – month: 06 year: 2014 text: June 2014 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Hoboken |
PublicationTitle | American journal of medical genetics. Part A |
PublicationTitleAlternate | Am. J. Med. Genet |
PublicationYear | 2014 |
Publisher | Blackwell Publishing Ltd Wiley Subscription Services, Inc |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley Subscription Services, Inc |
References | Neary WJ, Hillier VF, Flute T, Stephens SD, Ramsden RT, Evans DG. 2010b. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291-299. MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES. 2005. Diagnostic criteria for schwannomatosis. Neurology 64:1838-1845. Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR. 2009. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: Determination on whole-body MR images. Radiology 250:665-673. Pride NA, Payne JM, North KN. 2012. The impact of ADHD on the cognitive and academic functioning of children with NF1. Dev Neuropsychol 37:590-600. Lu-Emerson C, Plotkin S. 2009a. The neurofibromatoses. Part 1: NF1. Rev Neurol Dis 6:E47-E53. Lu-Emerson C, Plotkin S. 2009b. The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis 6:E81-E86. Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. 1990. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 113:39-52. Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A. 2001. Quality-of-life impairment in neurofibromatosis type 1: A cross-sectional study of 128 cases. Arch Dermatol 137:1421-1425. Neary WJ, Hillier VF, Flute T, Stephens SDG, Ramsden RT, Evans DG. 2010a. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291-299. Kayl AE, Moore BD III. 2000. Behavioral phenotype of neurofibromatosis, type 1. Ment Retard Dev Disabil Res Rev 6:117-124. Hyman SL, Shores A, North KN. 2005. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037-1044. Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S, Merker VL, Munn LL, Muzikansky A, Askenazi M, Nguyen R, Wenzel R, Mautner VF. 2012. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS ONE 7:e35711. Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. 2005. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26:93-97. Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. 2006. Impact of neurofibromatosis 1 on quality of life: A cross-sectional study of 176 American cases. Am J Med Genet Part A 140A:1893-1898. Kodra Y, Giustini S, Divona L, Porciello R, Calviei S, Wolkenstein P, Taruscio D. 2009. Health-related quality of life in patients with neurofibromatosis type 1. Dermatology 218:215-220. Granstrom S, Langenbruch A, Augustin M, Mautner VF. 2012. Psychological burden in adult neurofibromatosis type 1 patients: Impact of disease visibility on body image. Dermatology 224:160-167. Ware JE Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. 2007. User's manual for the Sf-36v2 health survey, 2nd edition. Lincoln, RI: QualityMetric Incorporated. Friedman JM. 1999. Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1-6. Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. 2012. Clinical features of schwannomatosis: A retrospective analysis of 87 patients. Oncologist 17:1317-1322. Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. 2002. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59:1759-1765. Mautner VF, Granstrom S, Leark RA. 2012. Impact of ADHD in adults with neurofibromatosis type 1: Associated psychological and social problems. J Atten Disord [Epub ahead of print]. 2006; 140A 2002; 59 2000; 6 2012 2009a; 6 2009b; 6 2010a; 35 2011 1999; 89 2005; 64 2007 2005; 65 2009; 250 2012; 17 2012; 37 2005; 26 2012; 224 2009; 218 1990; 113 2012; 7 2010b; 35 2001; 137 e_1_2_6_21_1 Ware JE (e_1_2_6_23_1) 2007 e_1_2_6_20_1 Lu‐Emerson C (e_1_2_6_11_1) 2009; 6 e_1_2_6_9_1 e_1_2_6_8_1 e_1_2_6_19_1 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_13_1 Ware JE (e_1_2_6_22_1) 2011 Lu‐Emerson C (e_1_2_6_10_1) 2009; 6 e_1_2_6_14_1 e_1_2_6_24_1 e_1_2_6_3_1 e_1_2_6_2_1 e_1_2_6_12_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_15_1 e_1_2_6_16_1 |
References_xml | – reference: Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR. 2012. Clinical features of schwannomatosis: A retrospective analysis of 87 patients. Oncologist 17:1317-1322. – reference: Ware JE Jr, Kosinski M, Bjorner JB, Turner-Bowker DM, Gandek B, Maruish ME. 2007. User's manual for the Sf-36v2 health survey, 2nd edition. Lincoln, RI: QualityMetric Incorporated. – reference: Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P. 2006. Impact of neurofibromatosis 1 on quality of life: A cross-sectional study of 176 American cases. Am J Med Genet Part A 140A:1893-1898. – reference: Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR. 2009. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: Determination on whole-body MR images. Radiology 250:665-673. – reference: Kayl AE, Moore BD III. 2000. Behavioral phenotype of neurofibromatosis, type 1. Ment Retard Dev Disabil Res Rev 6:117-124. – reference: Lu-Emerson C, Plotkin S. 2009a. The neurofibromatoses. Part 1: NF1. Rev Neurol Dis 6:E47-E53. – reference: Friedman JM. 1999. Epidemiology of neurofibromatosis type 1. Am J Med Genet 89:1-6. – reference: Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S, Merker VL, Munn LL, Muzikansky A, Askenazi M, Nguyen R, Wenzel R, Mautner VF. 2012. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS ONE 7:e35711. – reference: Granstrom S, Langenbruch A, Augustin M, Mautner VF. 2012. Psychological burden in adult neurofibromatosis type 1 patients: Impact of disease visibility on body image. Dermatology 224:160-167. – reference: Neary WJ, Hillier VF, Flute T, Stephens SD, Ramsden RT, Evans DG. 2010b. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291-299. – reference: Mulvihill JJ, Parry DM, Sherman JL, Pikus A, Kaiser-Kupfer MI, Eldridge R. 1990. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med 113:39-52. – reference: Hyman SL, Shores A, North KN. 2005. The nature and frequency of cognitive deficits in children with neurofibromatosis type 1. Neurology 65:1037-1044. – reference: Lu-Emerson C, Plotkin S. 2009b. The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis 6:E81-E86. – reference: Evans DG, Moran A, King A, Saeed S, Gurusinghe N, Ramsden R. 2005. Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10-year period: higher incidence than previously thought. Otol Neurotol 26:93-97. – reference: Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. 2002. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 59:1759-1765. – reference: Neary WJ, Hillier VF, Flute T, Stephens SDG, Ramsden RT, Evans DG. 2010a. The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form-36. Clin Otolaryngol 35:291-299. – reference: Pride NA, Payne JM, North KN. 2012. The impact of ADHD on the cognitive and academic functioning of children with NF1. Dev Neuropsychol 37:590-600. – reference: Kodra Y, Giustini S, Divona L, Porciello R, Calviei S, Wolkenstein P, Taruscio D. 2009. Health-related quality of life in patients with neurofibromatosis type 1. Dermatology 218:215-220. – reference: Mautner VF, Granstrom S, Leark RA. 2012. Impact of ADHD in adults with neurofibromatosis type 1: Associated psychological and social problems. J Atten Disord [Epub ahead of print]. – reference: MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES. 2005. Diagnostic criteria for schwannomatosis. Neurology 64:1838-1845. – reference: Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A. 2001. Quality-of-life impairment in neurofibromatosis type 1: A cross-sectional study of 128 cases. Arch Dermatol 137:1421-1425. – year: 2012 article-title: Impact of ADHD in adults with neurofibromatosis type 1: Associated psychological and social problems publication-title: J Atten Disord – year: 2011 – volume: 113 start-page: 39 year: 1990 end-page: 52 article-title: NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update publication-title: Ann Intern Med – volume: 59 start-page: 1759 year: 2002 end-page: 1765 article-title: Evaluation of clinical diagnostic criteria for neurofibromatosis 2 publication-title: Neurology – volume: 250 start-page: 665 year: 2009 end-page: 673 article-title: Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: Determination on whole‐body MR images publication-title: Radiology – volume: 35 start-page: 291 year: 2010b end-page: 299 article-title: The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form‐36 publication-title: Clin Otolaryngol – volume: 218 start-page: 215 year: 2009 end-page: 220 article-title: Health‐related quality of life in patients with neurofibromatosis type 1 publication-title: Dermatology – volume: 137 start-page: 1421 year: 2001 end-page: 1425 article-title: Quality‐of‐life impairment in neurofibromatosis type 1: A cross‐sectional study of 128 cases publication-title: Arch Dermatol – volume: 89 start-page: 1 year: 1999 end-page: 6 article-title: Epidemiology of neurofibromatosis type 1 publication-title: Am J Med Genet – volume: 6 start-page: 117 year: 2000 end-page: 124 article-title: Behavioral phenotype of neurofibromatosis, type 1 publication-title: Ment Retard Dev Disabil Res Rev – volume: 35 start-page: 291 year: 2010a end-page: 299 article-title: The relationship between patients' perception of the effects of neurofibromatosis type 2 and the domains of the Short Form‐36 publication-title: Clin Otolaryngol – volume: 37 start-page: 590 year: 2012 end-page: 600 article-title: The impact of ADHD on the cognitive and academic functioning of children with NF1 publication-title: Dev Neuropsychol – volume: 6 start-page: E81 year: 2009b end-page: E86 article-title: The neurofibromatoses. Part 2: NF2 and schwannomatosis publication-title: Rev Neurol Dis – volume: 224 start-page: 160 year: 2012 end-page: 167 article-title: Psychological burden in adult neurofibromatosis type 1 patients: Impact of disease visibility on body image publication-title: Dermatology – year: 2007 – volume: 140A start-page: 1893 year: 2006 end-page: 1898 article-title: Impact of neurofibromatosis 1 on quality of life: A cross‐sectional study of 176 American cases publication-title: Am J Med Genet Part A – volume: 26 start-page: 93 year: 2005 end-page: 97 article-title: Incidence of vestibular schwannoma and neurofibromatosis 2 in the North West of England over a 10‐year period: higher incidence than previously thought publication-title: Otol Neurotol – volume: 7 start-page: e35711 year: 2012 article-title: Quantitative assessment of whole‐body tumor burden in adult patients with neurofibromatosis publication-title: PLoS ONE – volume: 6 start-page: E47 year: 2009a end-page: E53 article-title: The neurofibromatoses. Part 1: NF1 publication-title: Rev Neurol Dis – volume: 64 start-page: 1838 year: 2005 end-page: 1845 article-title: Diagnostic criteria for schwannomatosis publication-title: Neurology – volume: 17 start-page: 1317 year: 2012 end-page: 1322 article-title: Clinical features of schwannomatosis: A retrospective analysis of 87 patients publication-title: Oncologist – volume: 65 start-page: 1037 year: 2005 end-page: 1044 article-title: The nature and frequency of cognitive deficits in children with neurofibromatosis type 1 publication-title: Neurology – ident: e_1_2_6_5_1 doi: 10.1002/(SICI)1096-8628(19990326)89:1<1::AID-AJMG3>3.0.CO;2-8 – ident: e_1_2_6_8_1 doi: 10.1002/1098-2779(2000)6:2<117::AID-MRDD5>3.0.CO;2-X – ident: e_1_2_6_17_1 doi: 10.1111/j.1749-4486.2010.02176.x – ident: e_1_2_6_6_1 doi: 10.1159/000337548 – ident: e_1_2_6_20_1 doi: 10.1080/87565641.2012.695831 – ident: e_1_2_6_16_1 doi: 10.1111/j.1749-4486.2010.02176.x – ident: e_1_2_6_13_1 doi: 10.1177/1087054712450749 – volume: 6 start-page: E81 year: 2009 ident: e_1_2_6_11_1 article-title: The neurofibromatoses. Part 2: NF2 and schwannomatosis publication-title: Rev Neurol Dis – ident: e_1_2_6_21_1 – ident: e_1_2_6_19_1 doi: 10.1371/journal.pone.0035711 – volume-title: User's manual for the Sf‐36v2 health survey year: 2011 ident: e_1_2_6_22_1 – ident: e_1_2_6_3_1 doi: 10.1148/radiol.2503080700 – ident: e_1_2_6_24_1 doi: 10.1001/archderm.137.11.1421 – ident: e_1_2_6_12_1 doi: 10.1212/01.WNL.0000163982.78900.AD – ident: e_1_2_6_7_1 doi: 10.1212/01.wnl.0000179303.72345.ce – ident: e_1_2_6_2_1 doi: 10.1212/01.WNL.0000035638.74084.F4 – volume-title: User's manual for the Sf‐36v2 health survey year: 2007 ident: e_1_2_6_23_1 – ident: e_1_2_6_4_1 doi: 10.1097/00129492-200501000-00016 – ident: e_1_2_6_18_1 doi: 10.1002/ajmg.a.31422 – ident: e_1_2_6_9_1 doi: 10.1159/000187594 – volume: 6 start-page: E47 year: 2009 ident: e_1_2_6_10_1 article-title: The neurofibromatoses. Part 1: NF1 publication-title: Rev Neurol Dis – ident: e_1_2_6_14_1 doi: 10.1634/theoncologist.2012-0162 – ident: e_1_2_6_15_1 doi: 10.7326/0003-4819-113-1-39 |
SSID | ssj0030576 |
Score | 2.2821622 |
Snippet | Patients with neurofibromatosis 1 (NF1), NF2, and schwannomatosis share a predisposition to develop multiple nerve sheath tumors. Previous studies have... |
SourceID | proquest pubmed crossref wiley istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1431 |
SubjectTerms | Adolescent Adult Aged Aged, 80 and over Attention Deficit Disorder with Hyperactivity - diagnosis Attention Deficit Disorder with Hyperactivity - psychology Female Humans Magnetic Resonance Imaging Male Middle Aged Nerve Sheath Neoplasms - complications Nerve Sheath Neoplasms - psychology nerve sheath tumor Neurilemmoma - complications Neurilemmoma - psychology Neurofibromatoses - complications Neurofibromatoses - psychology neurofibromatosis 1 Neurofibromatosis 1 - diagnostic imaging Neurofibromatosis 1 - pathology Neurofibromatosis 1 - psychology neurofibromatosis 2 Neurofibromatosis 2 - diagnostic imaging Neurofibromatosis 2 - pathology Neurofibromatosis 2 - psychology pain Pain - complications Pain Measurement quality of life Quality of Life - psychology Radiography schwannomatosis SF-36 Skin Neoplasms - complications Skin Neoplasms - psychology Surveys and Questionnaires Tumor Burden whole-body MRI Young Adult |
Title | Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis |
URI | https://api.istex.fr/ark:/67375/WNG-PR49C4G2-8/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fajmg.a.36466 https://www.ncbi.nlm.nih.gov/pubmed/24664633 https://www.proquest.com/docview/1521734319 https://www.proquest.com/docview/1523404348 https://www.proquest.com/docview/1529953199 |
Volume | 164A |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELZQEYgLlPIXKMhIwIV6m8SOEx9XFd2q0laooqI3yz9JWdom1WZXsD3xCH3GPkk9jjdQBJXgZinjyHZm7C_jmW8QemNtmqqkMkSkmhGmWEG0iSkptaDCnUA6ziF3eLzHdw7Y7mF2GBxukAvT8UP0DjewDL9fg4Er3W7-JA1VX0-PBmpAOePAuJ24BmCi_Z49ymmyry0HJGOEuT-hEPfuum_-2vnaiXQbFvf7n-DmdfTqj5_tB0guB95FnRwP5jM9MOe_cTr-_8xW0f2ATPGwU6WH6FZZr6E7Xa3KxRq6Ow638I_QeR9B92VyhkOkF_4GlXYvf1zoxi7wbH7aTLH2ORIbeJl-iSGgrAGv7wZWtcVdRucCNxU-mVQlntQ48Ly2GBzE2LNtVm4yjQPWTTtpH6OD7Q-ftnZIqOFADMspJ4o6AFAYnmvgSsupZVXu_iiTQglqMiEM5aVDHVw5pGLiTPO0MCpnlumSCssNfYJW6qYunyHsoKdJKs-fr1hZUV0lMbXGuq0-E0VsIvR--R2lCQTnUGfjRHbUzKmEhZVK-oWN0Nte-qwj9viL3DuvEr2Qmh5DMFyeyc97I_lxn4ktNkplEaH1pc7IsA-0EtBRTh1IExF63T92FgzXMqoum7mXocBxxIobZYSA7dK952mnj_2AUqgQwCmNEPFadeN05HB3PBr65vN_lH-B7jm0yLo4uXW0MpvOy5cOkc30K293VxuVMYg |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BK6AXHuXRlAJGAi5tttnYceLjqqK7lO4KVa3ozdhO0i5tk2ofKtsTP4HfyC_B42QDRVAJcYuUcWQ7M_bn8cw3AK_SNAxVOze-CDXzmWKJr01A_UwLKuwOpIMYc4f7A947YDuH0WFd5xRzYSp-iMbhhpbh1ms0cHRIb_5kDVWfz45aqkU54_wmLLorOkRFew1_lNVlV10OacZ8Zs9CdeS7bb_5a-sre9IiTu-XPwHOq_jVbUDb9-DTvOtV3MlJazrRLXP5G6vjf4ztPtytwSnpVNr0AG5kxTLcqspVzpbhdr--iH8Il00Q3fHwnNTBXuQCi-1-__pNl-mMTKZn5YholyaxQeYZmARjykp0_G4QVaSkSuqckTInp8M8I8OC1FSvY4I-YuIIN3M7mtJi63I8HD-Cg-23-1s9vy7j4BsWU-4rajFAYniskS4tpinLY3uobCdKUBMJYSjPLPDgyoIVE0Sah4lRMUuZzqhIuaGPYaEoi2wFiEWfpp07Cn3FspzqvB3Q1KR2tY9EEhgP1uc_Upqa4xxLbZzKip05lDixUkk3sR68bqTPK26Pv8i9cTrRCKnRCcbDxZH8OOjKD3tMbLFuKBMP1uZKI-ulYCwRIMXU4jThwcvmtTVivJlRRVZOnQxFmiOWXCsjBK6Y9jtPKoVsOhRikQBOqQe-U6trhyM7O_1uxz2u_qP8C7jT2-_vyt13g_dPYcmCR1aFza3BwmQ0zZ5ZgDbRz50R_gAcgzWm |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BKyouPMorUMBIwIVmm429TnxcFXZLYVdVRUVvlh8J3T6S1T4E2xM_gd_IL8HjZANFUAlukTKObGc889me-QbgubVxrNq5CUWsWcgUS0NtIhpmWlDhPJCOEswdHgz5zgHbPewc1gdumAtT8UM0B264Mry9xgU-tvnWT9JQdXz2qaValDPOr8Iq485TIijab-ijnCr74nLIMhYytxWqA99d-61fW19wSas4u1_-hDcvwlfvf3o3QS57XoWdnLTmM90y57-ROv7_0G7BjRqakm6lS7fhSlasw7WqWOViHdYG9TX8HThvQuiORmNSh3qRz1hq9_vXb7q0CzKbn5UTon2SxCZZ5l8SjCgr8dh3k6jCkiqlc0HKnJyO8oyMClITvU4JnhATT7eZu8GUDlmX09H0Lhz03nzY3gnrIg6hYQnloaIOAaSGJxrJ0hJqWZ64LWU7VYKajhCG8szBDq4cVDFRR_M4NSphlumMCssNvQcrRVlkD4A47GnauSfQVyzLqc7bEbXGOlvfEWlkAni1_I_S1AznWGjjVFbczLHEiZVK-okN4EUjPa6YPf4i99KrRCOkJicYDZd05MdhX-7tM7HN-rFMA9hY6oysDcFUIjxKqENpIoBnzWu3hPFeRhVZOfcyFEmOWHqpjBBoL9137lf62HQoxhIBnNIAQq9Vlw5HdncH_a5_fPiP8k9hbe91T75_O3z3CK475MiqmLkNWJlN5tljh85m-olfgj8AVNc0VQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relationship+between+whole-body+tumor+burden%2C+clinical+phenotype%2C+and+quality+of+life+in+patients+with+neurofibromatosis&rft.jtitle=American+journal+of+medical+genetics.+Part+A&rft.au=Merker%2C+Vanessa+L&rft.au=Bredella%2C+Miriam+A&rft.au=Cai%2C+Wenli&rft.au=Kassarjian%2C+Ara&rft.date=2014-06-01&rft.eissn=1552-4833&rft.volume=164A&rft.issue=6&rft.spage=1431&rft_id=info:doi/10.1002%2Fajmg.a.36466&rft_id=info%3Apmid%2F24664633&rft.externalDocID=24664633 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1552-4825&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1552-4825&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1552-4825&client=summon |